ANGLE plc (LSE:AGL) has announced a major scientific milestone with the publication of new research in Nature Genetics that leverages its Parsortix system to explore the genetic complexity of circulating tumor cell (CTC) clusters. Conducted by Professor Nicola Aceto’s team, the study reveals that CTC clusters play a pivotal role in cancer metastasis and therapy resistance, offering new insights into how tumors evolve and spread.
The findings highlight that CTC clusters are significantly more metastatic than single CTCs and serve as reservoirs of genetic diversity, potentially driving resistance to treatment. These insights reinforce the clinical value of targeting CTC clusters in cancer management, and demonstrate the advanced capabilities of ANGLE’s technology in supporting next-generation oncology research.
About ANGLE plc
ANGLE plc is a pioneer in liquid biopsy technologies, focusing on solutions based on circulating tumor cells for cancer research, drug development, and clinical diagnostics. Its flagship product, the Parsortix PC1 System—cleared by the FDA—is designed to capture and harvest CTCs from patient blood samples for detailed molecular analysis. Supported by more than 100 peer-reviewed studies, ANGLE is at the forefront of advancing precision oncology through non-invasive diagnostics and research tools.
Leave a Reply